- Home
- DTIL
as 01-17-2025 4:00pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 44.1M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $19.43 | Next Earning Date: | 11-04-2024 |
| Revenue: | $75,096,000 | Revenue Growth: | 43.62% |
| Revenue Growth (this year): | 52.95% | Revenue Growth (next year): | -72.59% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Germano Geno J | DTIL | Director | Dec 30 '24 | Buy | $4.49 | 3,605 | $16,186.45 | 7,807 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Dec 27 '24 | Buy | $4.75 | 2,113 | $10,036.75 | 40,186 | |
| Buehler Kevin | DTIL | Director | Dec 27 '24 | Buy | $4.88 | 4,320 | $21,081.60 | 8,712 | |
| Brown Melinda | DTIL | Director | Dec 26 '24 | Buy | $4.55 | 3,016 | $13,722.80 | 7,218 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Nov 21 '24 | Buy | $6.76 | 3,000 | $20,280.00 | 40,186 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Nov 2 '24 | Sell | $8.19 | 588 | $4,815.72 | 7,969 | |
| Amoroso Michael | DTIL | President and CEO | Nov 2 '24 | Sell | $8.19 | 3,012 | $24,668.28 | 28,537 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Precision BioSciences Shares Up After Upgrade From BMO Capital, Positive Date From Gene Therapy Study
MT Newswires
9 days ago
BMO Capital Upgrades Precision BioSciences to Outperform From Market Perform, Price Target is $34
Business Wire
10 days ago
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Business Wire
10 days ago
iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Argus Research
16 days ago
Daily – Vickers Top Buyers & Sellers for 01/03/2025
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 12/31/2024
Clinical Trials Arena
a month ago
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
Business Wire
a month ago
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.